Global Head and Neck Cancer Therapeutics Market, 2027

1. 2017 – 2027 GLOBAL HEAD AND NECK CANCER THERAPEUTICS MARKET FORECAST & OPPORTUNITIES www.techsciresearch.com MARKET INTELLIGENCE . CONSULTING

2. Scope of Report Product of Interest (POI): Head and Neck Cancer Therapeutics Head and neck cancer is a term used to define cancer that develops in the mouth, throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these cancers are squamous cell carcinomas, or cancers that begin in the lining of the mouth, nose and throat. Market Segmentation DISEASE INDICATION DIAGNOSTIC METHODS ROUTE OF ADMINISTRATION Year Range Lip and Oral Cavity Cancer • Injectable • Biopsy • Laryngeal Cancer • Oral • Imaging • Review Period Oropharyngeal Cancer • Endoscopy • Salivary Gland Cancer • 2017 – 2020 THERAPEUTIC CLASS Others • Nasopharyngeal Cancer • PD Inhibitors • Base Year Hypopharyngeal Cancer • EGFR Inhibitors • TREATMENT TYPE 2021 Microtubule Inhibitors • Surgery • Estimated Year Radiation Therapy • REGION END USER Chemotherapy • 2022 North America • Hospitals • Immunotherapy • Europe • Specialty Clinics • Forecast Period Targeted Therapy • APAC • Ambulatory Surgical Centers • 2023 – 2027 South America • Others • Middle East & Africa • 2

3. Table of Contents S. No. Contents Page No. Product Overview (A brief description of the category and product inclusions considered under the scope of the study to give clear picture to the client about the product of interest.) 1. Research Methodology (A detailed methodology on how we have derived the market related information and what are the measures that has been taken to validate the data.) 2. 3. Executive Summary 4. Voice of Customer Global Head and Neck Cancer Therapeutics Market Outlook, 2017-2027F (This chapter includes a brief overview of the product of interest market such as total market’s growth rate, expected growth rate, key growth levers, leading region, top grossing product types, etc. It includes more of a qualitative information about the market.) 5. 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others) By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy) 5.2.2. By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer) 5.2.3. 5.2.4. By Route of Administration (Injectable, Oral) 5.2.5. By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors) 5.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) 5.2.7. By Company (2021) 5.2.8. By Region 5.3. Product Market Map 3

4. Table of Contents S. No. Contents Page No. 6. Asia-Pacific Head and Neck Cancer Therapeutics Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Diagnostic Methods 6.2.2. By Treatment Type 6.2.3. By Disease Indication 6.2.4. By Route of Administration 6.2.5. By Therapeutic Class 6.2.6. By End-User 6.2.7. By Country 6.3. Asia-Pacific: Country Analysis 6.3.1. China Head and Neck Cancer Therapeutics Market Outlook 6.3.1.1. Market Size & Forecast By Value 6.3.1.1.1. 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Diagnostic Methods 6.3.1.2.2. By Treatment Type 6.3.1.2.3. By Disease Indication 6.3.1.2.4. By Route of Administration 6.3.1.2.5. By Therapeutic Class 6.3.1.2.6. By End-User 4

5. Table of Contents S. No. Contents Page No. 6.3.2. India Head and Neck Cancer Therapeutics Market Outlook 6.3.2.1. Market Size & Forecast By Value 6.3.2.1.1. 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Diagnostic Methods 6.3.2.2.2. By Treatment Type 6.3.2.2.3. By Disease Indication 6.3.2.2.4. By Route of Administration 6.3.2.2.5. By Therapeutic Class 6.3.2.2.6. By End-User 6.3.3. Japan Head and Neck Cancer Therapeutics Market Outlook 6.3.3.1. Market Size & Forecast By Value 6.3.3.1.1. 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Diagnostic Methods 6.3.3.2.2. By Treatment Type 6.3.3.2.3. By Disease Indication 6.3.3.2.4. By Route of Administration 6.3.3.2.5. By Therapeutic Class 6.3.3.2.6. By End-User 5

6. Table of Contents S. No. Contents Page No. 6.3.4. South Korea Head and Neck Cancer Therapeutics Market Outlook 6.3.4.1. Market Size & Forecast By Value 6.3.4.1.1. 6.3.4.2. Market Share & Forecast 6.3.4.2.1. By Diagnostic Methods 6.3.4.2.2. By Treatment Type 6.3.4.2.3. By Disease Indication 6.3.4.2.4. By Route of Administration 6.3.4.2.5. By Therapeutic Class 6.3.4.2.6. By End-User 6.3.5. Australia Head and Neck Cancer Therapeutics Market Outlook 6.3.5.1. Market Size & Forecast By Value 6.3.5.1.1. 6.3.5.2. Market Share & Forecast 6.3.5.2.1. By Diagnostic Methods 6.3.5.2.2. By Treatment Type 6.3.5.2.3. By Disease Indication 6.3.5.2.4. By Route of Administration 6.3.5.2.5. By Therapeutic Class 6.3.5.2.6. By End-User 6

7. Table of Contents S. No. Contents Page No. 6.3.6. Singapore Head and Neck Cancer Therapeutics Market Outlook 6.3.6.1. Market Size & Forecast By Value 6.3.6.1.1. 6.3.6.2. Market Share & Forecast 6.3.6.2.1. By Diagnostic Methods 6.3.5.2.2. By Treatment Type 6.3.6.2.3. By Disease Indication 6.3.6.2.4. By Route of Administration 6.3.6.2.5. By Therapeutic Class 6.3.6.2.6. By End-User 7. Europe Head and Neck Cancer Therapeutics Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Diagnostic Methods 7.2.2. By Treatment Type 7.2.3. By Disease Indication 7.2.4. By Route of Administration 7.2.5. By Therapeutic Class 7.2.6. By End-User 7.2.7. By Country 7

8. Table of Contents S. No. Contents Page No. 7.3. Europe: Country Analysis 7.3.1. France Head and Neck Cancer Therapeutics Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Diagnostic Methods 7.3.1.2.2. By Treatment Type 7.3.1.2.3. By Disease Indication 7.3.1.2.4. By Route of Administration 7.3.1.2.5. By Therapeutic Class 7.3.1.2.6. By End-User 7.3.2. Germany Head and Neck Cancer Therapeutics Market Outlook 7.3.2.1. Market Size & Forecast By Value 7.3.2.1.1. 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Diagnostic Methods 7.3.2.2.2. By Treatment Type 7.3.2.2.3. By Disease Indication 7.3.2.2.4. By Route of Administration 7.3.2.2.5. By Therapeutic Class 7.3.2.2.6. By End-User 8

9. Table of Contents S. No. Contents Page No. 7.3.3. United Kingdom Head and Neck Cancer Therapeutics Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Diagnostic Methods 7.3.3.2.2. By Treatment Type 7.3.3.2.3. By Disease Indication 7.3.3.2.4. By Route of Administration 7.3.3.2.5. By Therapeutic Class 7.3.3.2.6. By End-User 7.3.4. Italy Head and Neck Cancer Therapeutics Market Outlook 7.3.4.1. Market Size & Forecast By Value 7.3.4.1.1. 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Diagnostic Methods 7.3.4.2.2. By Treatment Type 7.3.4.2.3. By Disease Indication 7.3.4.2.4. By Route of Administration 7.3.4.2.5. By Therapeutic Class 7.3.4.2.6. By End-User 9

10. Table of Contents S. No. Contents Page No. 7.3.5. Spain Head and Neck Cancer Therapeutics Market Outlook 7.3.5.1. Market Size & Forecast By Value 7.3.5.1.1. 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Diagnostic Methods 7.3.5.2.2. By Treatment Type 7.3.5.2.3. By Disease Indication 7.3.5.2.4. By Route of Administration 7.3.5.2.5. By Therapeutic Class 7.3.5.2.6. By End-User 8. North America Head and Neck Cancer Therapeutics Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Diagnostic Methods 8.2.2. By Treatment Type 8.2.3. By Disease Indication 8.2.4. By Route of Administration 8.2.5. By Therapeutic Class 8.2.6. By End-User 8.2.7. By Country 10

11. Table of Contents S. No. Contents Page No. 8.3. North America: Country Analysis United States Head and Neck Cancer Therapeutics Market Outlook 8.3.1. 8.3.1.1. Market Size & Forecast By Value 8.3.1.1.1. 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Diagnostic Methods 8.3.1.2.2. By Treatment Type 8.3.1.2.3. By Disease Indication 8.3.1.2.4. By Route of Administration 8.3.1.2.5. By Therapeutic Class 8.3.1.2.6. By End-User 8.3.2. Mexico Head and Neck Cancer Therapeutics Market Outlook 8.3.2.1. Market Size & Forecast By Value 8.3.2.1.1. 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Diagnostic Methods 8.3.2.2.2. By Treatment Type 8.3.2.2.3. By Disease Indication 8.3.2.2.4. By Route of Administration 8.3.2.2.5. By Therapeutic Class 8.3.2.2.6. By End-User 11

12. Table of Contents S. No. Contents Page No. 8.3.3. Canada Head and Neck Cancer Therapeutics Market Outlook 8.3.2.1. Market Size & Forecast By Value 8.3.2.1.1. 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Diagnostic Methods 8.3.2.2.2. By Treatment Type 8.3.2.2.3. By Disease Indication 8.3.2.2.4. By Route of Administration 8.3.2.2.5. By Therapeutic Class 8.3.2.2.6. By End-User 9. South America Head and Neck Cancer Therapeutics Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Diagnostic Methods 9.2.2. By Treatment Type 9.2.3. By Disease Indication 9.2.4. By Route of Administration 9.2.5. By Therapeutic Class 9.2.6. By End-User 9.2.7. By Country 12

13. Table of Contents S. No. Contents Page No. 9.3. South America: Country Analysis 9.3.1. Brazil Head and Neck Cancer Therapeutics Market Outlook 9.3.1.1. Market Size & Forecast By Value 9.3.1.1.1 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Diagnostic Methods 9.3.1.2.2. By Treatment Type 9.3.1.2.3. By Disease Indication 9.3.1.2.4. By Route of Administration 9.3.1.2.5. By Therapeutic Class 9.3.1.2.6. By End-User 9.3.2. Argentina Head and Neck Cancer Therapeutics Market Outlook 9.3.2.1. Market Size & Forecast By Value 9.3.2.1.1 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Diagnostic Methods 9.3.2.2.2. By Treatment Type 9.3.2.2.3. By Disease Indication 9.3.2.2.4. By Route of Administration 9.3.2.2.5. By Therapeutic Class 9.3.2.2.6. By End-User 13

14. Table of Contents S. No. Contents Page No. 9.3.3. Colombia Head and Neck Cancer Therapeutics Market Outlook 9.3.3.1. Market Size & Forecast By Value 9.3.3.1.1 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Diagnostic Methods 9.3.2.2.2. By Treatment Type 9.3.2.2.3. By Disease Indication 9.3.2.2.4. By Route of Administration 9.3.2.2.5. By Therapeutic Class 9.3.2.2.6. By End-User 10. Middle East & Africa Head and Neck Cancer Therapeutics Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Diagnostic Methods 10.2.2. By Treatment Type 10.2.3. By Disease Indication 10.2.4. By Route of Administration 10.2.5. By Therapeutic Class 10.2.6. By End-User 10.2.7. By Country 14

15. Table of Contents S. No. Contents Page No. 10.3. Middle East & Africa : Country Analysis South Africa Head and Neck Cancer Therapeutics Market Outlook 10.3.1. 10.3.1.1. Market Size & Forecast By Value 10.3.1.1.1. 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Diagnostic Methods 10.3.1.2.2. By Treatment Type 10.3.1.2.3. By Disease Indication 10.3.1.2.4. By Route of Administration 10.3.1.2.5. By Therapeutic Class 10.3.1.2.6. By End-User 10.3.2. Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook 10.3.2.1. Market Size & Forecast By Value 10.3.2.1.1. 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Diagnostic Methods 10.3.2.2.2. By Treatment Type 10.3.2.2.3. By Disease Indication 10.3.2.2.4. By Route of Administration 10.3.2.2.5. By Therapeutic Class 10.3.2.2.6. By End-User 15

16. Table of Contents S. No. Contents Page No. UAE Head and Neck Cancer Therapeutics Market Outlook 10.3.3. 10.3.3.1. Market Size & Forecast By Value 10.3.3.1.1. 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Diagnostic Methods 10.3.3.2.2. By Treatment Type 10.3.3.2.3. By Disease Indication 10.3.3.2.4. By Route of Administration 10.3.3.2.5. By Therapeutic Class 10.3.3.2.6. By End-User 11. Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market 12. Clinical Trial Analysis 13. Market Dynamics 13.1. Drivers 13.2. Challenges Market Trends & Developments (This section captures recent trends pertaining to manufacturing or consumption, market movements in terms of points of production and consumption, advancements and development) 14. 15. Competitive Landscape 16

17. Table of Contents S. No. Contents Page No. 15.1. Competition Outlook 15.2. Company Profiles (Top 10 Companies) 15.2.1. Company Details 15.2.2 Products & Services 15.2.3. Financials (As Reported) 15.2.4. Key Market Focus & Geographical Presence 15.2.5. Recent Developments 15.2.6. Key Management Personnel Strategic Recommendations (Based on the findings of the report strategic recommendations on how to enter and expand market share) 16. 17. About Us & Disclaimer 17

18. RESEARCH RESEARCH METHODOLOGY METHODOLOGY

19. Research Methodology Market Profiling Data Analysis Data Data Developing list of respondents Formulating Questionnaire Collection Validation In-depth secondary research was conducted to determine top players in the global head and neck cancer therapeutics market, overall market size and segmental market size. The data was scrutinized using MS-Excel, statistical tools and internal proprietary database to obtain qualitative and quantitative insights about the global head and neck cancer therapeuticsmarket Data obtained as a result of primary and secondary research was validated through rigorous triangulation. TechSci conducted interviews with industry experts and industry players for data collection and verification. In order to conduct industry experts’ interviews, TechSci formulated a detailed discussion guide. List of industry players and industry specialists was developed. Primary Research Desk Research Company Analysis ✓ ✓ Recent Developments Market Changing Aspects/Dynamics Government Policies Final Conclusion ✓ ✓ Market Participants Key Strengths ✓ Identifying Key Opinion Leaders Questionnaire Design In-depth Interviews Actionable Insights Data Filter & Analysis Business Solution Research & Intelligence Data Collection ✓ ✓ ✓ ✓ Primary Research Secondary Research Paid Sources LinkedIn TechSci Internal Database Company Website Company Annual Reports White Paper Study Financial Reports Investor Presentations Regulatory Body Associations, etc. Factiva Hoovers ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 19

20. Research Methodology Baseline Methodology Our dedicated team of industry experts has monitored and analyzed various aspects of global head and neck cancer therapeutics market. The team has analyzed the outlook of various segments of this market, while considering the major influencing factors such as rising patient pool suffering from head and neck cancer around the world and speculated a positive growth during the next 5 years. The study includes market forecasting, which would enable our clients to take better decisions while planning their strategy to achieve sustainability in global head and neck cancer therapeutics market. Methodology Followed for Calculation of Market Size: Market Size by Value: Market size, in terms of value, for the year 2021 was calculated based on information collected through exhaustive • secondary research and primary surveys, with various key opinion leaders/stakeholders, such as head and neck cancer therapeutics companies, channel partners, market influencers & end users, industry experts, and other industry participants. The team interviewed more than 15 – 20 head and neck cancer therapeutics companies, 45 – 50 channel partners, 80 – 100 end users, and • 15 – 20 Industry experts and other value chain stakeholders in global head and neck cancer therapeutics market to obtain the overall market size from 2017-2021, which was validated by the Delphi technique. Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data from 2017-2021. 20

21. Research Methodology Respondents were asked about the current and future market growth rates, market shares by diagnostic methods, by treatment type, by • disease indication, by route of administration, by therapeutic class, by end user, by company and by region. Removing the outlier responses, the geometric mean of growth estimates and supplier wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue shares generated across various segments were further triangulated from other stakeholders depending upon the type of head and neck cancer therapeutics. Methodology Followed for Calculation of Market Shares: Market shares by diagnostic methods, by treatment type, by disease indication, by route of administration, by therapeutic class, by end user, by company and by region were calculated based on the responses received through primary surveys with industry experts, in which the respondents were asked about the market shares or revenue generated from various type of head and neck cancer therapeutics. The final shares were calculated by taking the geometric mean of the responses gathered from key opinion leaders after eliminating the outliers. Methodology Followed for Forecasting: TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in • SPSS/Tableau Software. Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global head • and neck cancer therapeutics market, TechSci Research used various forecast techniques such as: Moving Average ✓ Time Series Analysis ✓ Regression Analysis ✓ Econometric and Judgmental Analysis ✓ 21

22. Research Methodology TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that the figures compiled are only for the organized market including market share data. Partial List of Companies Interviewed Key Secondary Sources AstraZeneca Plc. Astellas Pharma Inc. AB Science SA Bristol-Myers Squibb Company Boston Biomedical, Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. (Genentech, Inc.,) Fresenius Medical Care AG & Co. KGaA Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Limited Merck & Co., Inc. Pfizer Inc. Sanofi S.A. Bayer AG AbbVie Inc. World Bank TechSci Research Proprietary Database & Knowledge Repository Company Annual Reports Industry Magazines Industry Reports News Dailies ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ 22

23. Industry Brief The growing prevalence of different types of head and neck cancers is expected to drive the growth of Global Head and Neck Cancer Therapeutics through 2027. According to TechSci report on, “Global Head and Neck Cancer Therapeutics Market - By Region, Competition Forecast & Opportunities, 2027”. Global Head and Neck Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected to grow at an impressive rate of 7.22% during the forecast period. This can be ascribed to the growth in research and development activities related to cancer treatment and developing new treatment options. The rising incidence of various types of cancer has led to an increase in demand for developing therapies and drugs to treat them. This, in turn, has made many government agencies, academic & research institutions, and biotechnology & pharmaceutical companies focus on a new therapy or drug development. These organizations are increasing their research & development activities related to cancer diagnostics and therapeutics. However, there are a lot of complications and post-surgery risks associated with various head and neck cancer surgeries. These risks or complications include temporary or permanent loss of voice, hearing loss is also observed in certain cases, faulty speech, among others. Also, there are a lot of side effects associated with chemotherapy, including harm caused to the healthy cells and cancerous cells, loss of appetite, nausea, pain, vomiting, hair loss, tiredness, anemia, sleep problems, and others. Global Head and Neck Cancer Therapeutics Market is segmented by type, by diagnostic methods, by treatment type, by disease indication, by route of administration, by therapeutic class, by end user, by region and company. Based on type, the global head and neck cancer therapeutics market can be split into diagnostic methods and treatment types. Diagnostic methods dominated the market with a share of around 56.89% since Diagnostic methods form an integral part of the development of a treatment or therapy. Hence, accurate and precise diagnosis is required for developing the right treatment. Diagnostic Methods such as Biopsy, Imaging, and Endoscopy not only help in the early diagnosis and detection of cancer but are done during the treatment also in order to identify the cancer progression stages or whether the treatment provided is helping in the treatment and elimination of different types of head and neck cancer. Based on disease indication, the market can be fragmented into Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Nasopharyngeal Cancer, Salivary Gland Cancer and Hypopharyngeal Cancer. The Lip and Oral Cavity Cancer is expected to dominate the market through 2027 on account of the growing prevalence of this cancer type. According to Globocan, 377,713 new cases of lip and oral cavity cancer were reported in 2020 and along with this number of reported deaths caused due to lip and oral cancer were around 177,757. A partial list of leading companies in the Global Head and Neck Cancer Therapeutics Market includes Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc. The Asia Pacific region is expected to register the fastest growth during the forecast period. This can be attributed to the growing prevalence of different types of head and neck cancers in the region, especially in two of the world’s highly populated countries, China and India. Additionally, extensive research & development activities, ongoing clinical trials, increasing investments, expansion of companies along with their manufacturing sites in the region especially in countries like China, Japan, Singapore, among others for the development of therapies and drugs for the treatment of different types of head and neck cancers is further expected to support the market growth in the region.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm. 23

24. Sample Data - Snapshot Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017–2027F 15.00 14.00 13.00 12.00 11.00 10.00 9.00 8.00 7.00 6.00 5.00 CAGR By Value XX% CAGR By Value YY% 2017 2021 2022E 2027F North America Head and Neck Cancer Therapeutics Market Share, By Diagnostic Methods, By Value, 2017–2027F Biopsy Imaging Endoscopy Others 25% 25% 25% 25% 2027F 25% 25% 25% 25% 2026F 25% 25% 25% 25% 2025F 25% 25% 25% 25% 2024F 25% 25% 25% 25% 2023F 25% 25% 25% 25% 2022E 25% 25% 25% 25% 2021 25% 25% 25% 25% 2020 25% 25% 25% 25% 2019 25% 25% 25% 25% 2018 25% 25% 25% 25% 2017 North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Value, 2017–2027F Surgery Radiation Therapy Chemotherapy Immunotherapy Targeted Therapy 20% 20% 20% 20% 20% 2027F 20% 20% 20% 20% 20% 2026F 20% 20% 20% 20% 20% 2025F 20% 20% 20% 20% 20% 2024F 20% 20% 20% 20% 20% 2023F 20% 20% 20% 20% 20% 2022E 20% 20% 20% 20% 20% 2021 20% 20% 20% 20% 20% 2020 20% 20% 20% 20% 20% 2019 20% 20% 20% 20% 20% 2018 20% 20% 20% 20% 20% 2017 24

25. Report Ordering Report Name: GLOBAL HEAD AND NECK CANCER THERAPEUTICS MARKET FORECAST & OPPORTUNITIES 2017 – 2027 License Type Single User License Price $4900 Multi-User License Custom Research License $5900 $8900 To View Sample OR Purchase Report 25

26. About Us & Disclaimer TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high- quality reports. The proprietary forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the market. Related Reports Saudi Arabia CT Scanners Market By Slice (8-slice, 16-slice, 32-slice, 64-slice, 128-slice & above), By Modality (Fixed v/s Mobile), By Device Architecture (O-arm v/s C-arm), By Application (Cardiology, Oncology, Neurology, Others), By End Users (Hospitals, Diagnostic Centers, Others), By Region, Competition, Forecast & Opportunities, 2027 • Saudi Arabia X-Ray Systems Market By Modality (Direct Radiography v/s Computed Radiography) By Mobility (Stationary v/s Mobile) By Type (Digital v/s Analog) By Application (Cardiovascular, Respiratory, Dental, Mammography, Others) By End User (Hospitals & Clinics, Diagnostic Centers, Others) By Region, Competition Forecast & Opportunities, 2026 • TechSci Research – North America 708 Third Avenue, Manhattan, New York, United States Tel: +1- 646- 360- 1656 Email: sales@techsciresearch.com www.techsciresearch.com TechSci Research – Europe 54, Old brook, Bretton, Peterborough, United Kingdom Email: sales@techsciresearch.com www.techsciresearch.com TechSci Research – Asia-Pacific B – 44, Sector – 57, Noida, National Capital Region, U.P. - India Tel: +91-120-4523900 Email: sales@techsciresearch.com www.techsciresearch.com Disclaimer The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and first hand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.